Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption.https://bit.ly/3hCw5dq
No takes yet. Share an insight, caveat, or question.
Koningsbruggen-Rietschel et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: